Kiromic BioPharma, Inc. (KRBP)
USD 0.08
(-2.33%)
USD 0.08
(-2.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -19.93 Million USD | 35.92% |
| 2022 | -31.11 Million USD | -20.9% |
| 2021 | -25.73 Million USD | -34.06% |
| 2020 | -19.19 Million USD | -418.08% |
| 2019 | -3.7 Million USD | -16.43% |
| 2018 | -3.18 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -5.11 Million USD | 3.85% |
| 2024 Q2 | -6.35 Million USD | -24.25% |
| 2023 Q3 | -5.55 Million USD | -29.33% |
| 2023 Q4 | -5.31 Million USD | 4.21% |
| 2023 FY | -19.93 Million USD | 35.92% |
| 2023 Q1 | -4.77 Million USD | 30.97% |
| 2023 Q2 | -4.29 Million USD | 10.15% |
| 2022 Q3 | -8.39 Million USD | 0.43% |
| 2022 Q2 | -8.43 Million USD | -14.49% |
| 2022 FY | -31.11 Million USD | -20.9% |
| 2022 Q1 | -7.36 Million USD | 30.94% |
| 2022 Q4 | -6.92 Million USD | 17.57% |
| 2021 Q2 | -4.97 Million USD | -25.67% |
| 2021 FY | -25.73 Million USD | -34.06% |
| 2021 Q3 | -6.14 Million USD | -23.53% |
| 2021 Q4 | -10.66 Million USD | -73.63% |
| 2021 Q1 | -3.95 Million USD | -11.09% |
| 2020 Q2 | -11.36 Million USD | -513.53% |
| 2020 Q4 | -3.56 Million USD | -47.44% |
| 2020 Q3 | -2.41 Million USD | 78.75% |
| 2020 FY | -19.19 Million USD | -418.08% |
| 2020 Q1 | -1.85 Million USD | 14.61% |
| 2019 Q1 | -387.3 Thousand USD | 0.0% |
| 2019 FY | -3.7 Million USD | -16.43% |
| 2019 Q4 | -2.16 Million USD | -146.69% |
| 2019 Q3 | -879.5 Thousand USD | -226.95% |
| 2019 Q2 | -269 Thousand USD | 30.54% |
| 2018 FY | -3.18 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -3947.405% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -109.49% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 33.52% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 70.303% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -25.856% |
| Better Therapeutics, Inc. | -38.26 Million USD | 47.887% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 52.609% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -66.577% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 41.085% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 42.069% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 81.617% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -889.886% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 41.358% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 57.532% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -1358.206% |
| Molecular Templates, Inc. | -10.46 Million USD | -90.515% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -41.908% |
| NexImmune, Inc. | -29.19 Million USD | 31.697% |
| Orgenesis Inc. | -53.63 Million USD | 62.825% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 61.127% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -25457.635% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -23.499% |
| Scopus BioPharma Inc. | -11.71 Million USD | -70.205% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 96.046% |
| Statera Biopharma, Inc. | -98.34 Million USD | 79.725% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -189.059% |
| Trevena, Inc. | -35.28 Million USD | 43.496% |
| Vaxxinity, Inc. | -58.28 Million USD | 65.79% |
| Vaccinex, Inc. | -22.88 Million USD | 12.872% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -1804.462% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 60.667% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -174.532% |